Grifols, S.A. reports results for the quarter ended September 30 - Earnings Summary

By Reuters News
  • Grifols, S.A. reported quarterly adjusted earnings of 27 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 21 cents. The lone analyst forecast for the quarter was for earnings of 26 cents per share.

  • Revenue rose 9.4% to €2.04 billion from a year ago; analysts expected €1.97 billion.

  • Grifols, S.A.'s reported EPS for the quarter was 24 cents​.

  • The company reported quarterly net income of €162 million.

  • Grifols, S.A. shares had risen by 10.8% this quarter and lost 13.2% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 4.3% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

  • Wall Street's median 12-month price target for Grifols, S.A. is $11.73, about 30.9% above its last closing price of $8.10

This summary was machine generated from LSEG data November 2 at 08:07 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Sep. 30 2026

0.26

0.27

Beat

Jun. 30 2026

0.24

0.10

Missed

Mar. 31 2026

0.14

0.23

Beat

Dec. 31 2025

0.25

0.23

Missed

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.